Retatrutide dosing schedule Retatrutide dosage in clinical trials A phase 1 clinical trial of retatrutide involved 72 individuals with diagnosed type 2 diabetes who received 12 mg once weekly retatrutide injections subcutaneously for 12 weeks
Chan DC, Watts GF, Ng TWK, Yamashita S, Barrett PHR
Subscribe to save 20% and keep your routine uninterrupted
In the TRIUMPH-1 Phase 3 trial, participants on the maximum dose of retatrutide (12 mg) lost an average of 28.3% of their body weight after 80 weeks, and up to 30.3% after 104 weeks in the study extension
2 Conditional analysis of GLP1R locus
The Future of Metabolic Medicine in India With rising rates of obesity, insulin resistance, and metabolic syndrome in urban India, therapies like retatrutide represent a shift toward precision metabolic modulation